Kenneth Rand, M.D. Professor Department of Pathology, Immunology and Laboratory Medicine University of Florida College of Medicine Gainesville, Florida Publications

1. Rand, K.H., Houck, H. J., Lawrence, R. M. Real-Time Polymerase Chain Reaction of Herpes Simplex Virus in Cerebrospinal Fluid and Cost Savings from Earlier Hospital Discharge. J Mo Diagn 2005, 7;511-516.
2. Liu, P., Rand, K.H., Obermann, B., Derendorf, H. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 2005, 25:120-129.
3. Grier, D.D., Qiu, J., Rand, K., Donnelly, W.H. Pathologic quiz case: a 13-year-old boy with a 2-day history of fever, vomiting, and mental status changes. Chromobacterium violaceum bacteremia. Arch Pathol Lab Med 2004, 128:e131-e132.
4. Rand, K.H., Houck, H.J. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2004, 48:2871-2875.
5. Liu, Q., Rand, K., Derendorf, H. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations. Int J Antimicrob Agents 2004, 23:494-497.
6. de la Peña, A., Gräbe, A., Rand, K. H., Rehak, E., Gross, J., Thyroff-Friesinger, U., Müller, M., and Derendorf, H. PK-PD Modelling of the Effect of Cefaclor on Four Different Bacterial Strains. Int J Antimicrob.Agents 2004;23(3):218-25.
7. Rand, K.H. and Houck, H.: Daptomycin Synergy with Rifampicin and Ampicillin Against Vancomycin-Resistant Enterococci. J Antimicrob Chemother. 2004;53:530-532.
8. Netzel, T. and Rand, K. Prostatitis Associated with Corynebacterium glucuronolyticum. Clin Micr Newsl 24(12):94-95, 2002.
9. Rand, K.H., Houck, H.: Improved Methods for the Application of Random Peptide Phage Libraries to the Study of the Oligoclonal Bands in Cerebrospinal Fluid of Patients with Multiple Sclerosis. J. Neurol Sci. 2000 101:131-139.
10. Rand, K.H., Houck, H, Denslow, N.D., Heilman, K.M. Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) Associated Oligoclonal Bands in Patients with Multiple Sclerosis. J Neurol Sci 2000 173:32-39.
11. Langevin, P.B., Layon, A.J., Rand, K.H., Banner, M.J., Langevin, S.O.: Dissemination of   Mycobacterium Tuberculosis Through Anesthesia Breathing Circuits.  Chest 1999 155(4)1107-1114.
12. Rand, K.H., Houck, H, Denslow, N.D., Heilman, K.M.  Epstein-Barr Virus Nuclear Antigen-1 (EBNA-1) Associated Oligoclonal Bands in Patients with Multiple Sclerosis. J Neurol Sci 2000 173;32-39. 
13. Mehta, J.L, Saldeen, T. G. P., Rand, K.H.  Interactive Role of Infection, Inflammation, and Traditional Risk Factors in Atherosclerosis and Coronary Artery Disease. J Am Coll  Card. 1998 6;1217-25.
14. Davis, J.D., Riley, P.K., Peters, C. and Rand K.H.: A Comparison of Ligase Chain Reaction to Polymerase Chain Reaction in the Detection of Chlamydia trachomatis Endocervicitis. Infect Dis Obstet Gynecol 1998;6:57-60.
15. Rand, K.H., Houck, H, Denslow, N.D., Heilman, K.M.: Molecular Approach to Find Target(s) for Oligoclonal Bands in Multiple Sclerosis. J Neurol Neurosurg Psych. 1998;65:48-55.
16. Al-Abbadi, M., Wolff, M., Rand K.H., Baer H.:  Invasive Aspergillosis Preceded by Legionella Pneumonia:  A Report of Two Cases and Review of the Literature. J Histotechnol 1997;20:371-373.
17. Rand, K.H.:  Rejection Criteria for Endotracheal Aspirates in Neonates:  Clinical Impact. Diagn Microbiol Infect Dis, 1997;27:55-61.
18. Nolting, A., Costa, T.D., Vistelle, R., Rand, K.H. and Derendorf, H.: Determination of Free Extracellular Concentrations of Piperacillin by Microdialysis.  J Pharm Sci, 1996, 85 (4) 369-372.
19. Nolting, A., Costa, T.D., Rand, K.H. and Derendorf, H.: Pharmacokinetic-Pharmacodynamic Modeling of the Antibiotic Effect of Piperacillin in Vitro. Pharm Res, 1996, Volume 13, pp 91-96.
20. Rand, K.H. and Brown P.:  Concentration-Dependent Synergy and Antagonism Between Cefoperazone and Imipenem Against Methicillin-Resistant Staphylococcus Areus. Antimicrobial Agents and Chemotherapy, 1995, 39 (5) 1173-1177.
21. Rand, K.H., Houck, H.J. and Wolff, M.:  Detection of Candidemia by Polymerase Chain  Reaction.  Molecular Cell Probes, 1994,  8 (3) 215-221.
22. Wolff, M.A., Rand, K.H., Houck, H.J., Brunson, M.E., et al.:  Relationship of the Polymerase Chain Reaction for Cytomegalovirus to the Development of Hepatitis in Liver Transplant Recipients. Transplantation, 1993, 56 (3), 572-576.
23. Rand, K.H., Houck, H.J., Brown, P. and Bennet D.:  Reproducibility of the Microdilution   Checkerboard Method for Antibiotic Synergy. Antimicrobial Agents and Chemotherapy,   March 1993, 37(3), 613-615.
24. *Ramphal, R., Bolger, M., Oblon, D.J., Sherertz, R.J., Malone, J.D., Rand, K.H., et al.: Vancomycin is Not an Essential Component of the Initial Empiric Treatment Regimen for Febrile Neutropenic Patients Receiving Ceftazidime:  a Randomized Prospective Study. Antimicrobial Agents and Chemotherapy, 1992, 1992, Volume 36(5), 1062-1067.
25. *Rand, K.H., Gibbs, K., Derendorf, H., and Graham-Pole, J.:  Pharmacokinetics of Intravenous Immunoglobulin (GammagardR) in Bone Marrow Transplant Patients.  J. Clin. Pharmacol., 1991, Volume 31(12), 1151-1154. 
26. *Raad, I.I., Sabbagh, M.F., Rand, K.H., Sherertz, R.J.:  Quantitative Tip Culture Methods and the Diagnosis of Central enous Catheter-Related Infections.  Diagn Microbiol Infect Dis. 1992, Volume 15, pp. 13-20.
27. *Ramphal, R., Bolger, M., Oblon, D.J., Sherertz, R.J., Malone, J.D., Rand, K.H., Gilliom, M., Shands, Jr., J.W., and Kramer, B.S.:  Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving Ceftazidime:  a randomized prospective study. Antimicro Agents & Chemotherapy. 1992, Volume 36(5), pp. 1062-1067.
28. *Krischer, J., Elfenbein, G., Babington, R., Hong, J., Jansen, H., Lazarus, H., Winton, E. and Rand, K.H.:  Risk factors for cytomegalovirus pneumonia following allogeneic bone marrow transplantation after prophylaxis with intravenous immunoglobulin.  Sem Hematol. 1992, Volume 29(3), pp. 89-95.
29. *Judson, F.N., Eron, L.J., Lutz, F.B., Rand, K.H., Tennican, P.O. and Mogabgab, W.J.: Multicenter study of a single 500-mg dose of cefotaxime for treatment of uncomplicated gonorrhea. Sex Transm Dis. 1991, Volume 18(1), pp. 41-43.
30. *Hoon, E.F., Hoon, P.W., Rand, K.H., Johnson, J., Hall, N.R., and Edwards, N.B.:  A Psycho-Behavioral Model of Genital Herpes Recurrence.  J Psychosom Res.  1991, Volume 35(1), pp. 25-36.
31. *Elfenbein, G.J., Siddiqui, T., Rand, K.H., Graham-Pole, J., Marcus, R.B., Mendenhall, N.P., Goedert, T.M., Wikle-Fisher, T., Gross, S.A., and Weiner, R.S.:  Successful strategy for prevention of cytomegalovirus interstitial pneumonia after human leukocyte antigen-identical bone marrow transplantation. Rev Infect Dis. 1990, Volume 12(Suppl. 7), pp.      S805-S810.
32. *Raad, I., Rand, K.H. and Gaskins, D.:  Buffered charcoal-yeast extract medium for the isolation of Brucellae.  J. Clin Micro., 1990, Volume 28, pp. 1671-1672.
33. *Rand, K.H. and Houck, H.:  Taq polymerase contains bacterial DNA of unknown origin. Mol Cell Probes, 1990, Volume 4, 445-450.
34. *Johnson, M.P. and Rand, K.H.:  Group A  -streptococcal bacteremia and HIV infection.  S Med Journal, 1990, Volume 83, pp. 146-149.
35. *Rand, K.H., Hoon, E.F., Massey, J.K. and Johnson, J.H.:  Daily stress and recurrence of genital herpes simplex. Archives of Int. Med.  1990, Volume 150, 1889-1893.
36. *Sherertz, R.J., Raad, I.I., Belani, A., Koo, L.C., Rand, K.H., Pickett, D.L., Straub, S.A. and      Fauerbach, L.L.:  Three year experience with sonicated vascular catheter cultures in a      clinical microbiology laboratory.  J. Clin. Micro., 1989, Volume 28, pp. 76-82.
37. *Rand, K.H., Houck, H., Ganju, A., Babington, R.G. and Elfenbein, G.J.:       Pharmacokinetics of cytomegalovirus specific IgG antibody following intravenous      immunoglobulin in bone marrow transplant patients.  Bone Marrow Transplantation,      1989, Volume 4, pp. 679-683.
38. *Elfenbein, G., Krischer, J., Babington, R., Hong, R., Jansen, J., Lazarus, H., Winton, E.      and Rand, K.:  Interim results of a multicenter trial to prevent cytomegalovirus      pneumonia after allogeneic bone marrow transplantation.  Transplantation Proceedings      1989, Volume 21, 3099-3100.
39. *Elfenbein, G.J., Krischer, J.P., Rand, K.H., Graham-Pole, J., Babington, R.G.:       Prevention of cytomegalovirus interstitial pneumonitis after allogeneic bone marrow      transplantation:  A multicenter trial.  Clinical Immunol Newsletter, 1099. Volume 9, pp. 203-205.
40. *Rand, K.H., Raad, I., El Koussi, A.A., Houck, H., Brey, W., Rocca, J.; Loftsson, T.; and Bodor, N.:  Trifluorothymidine:  potential non-invasive diagnosis of herpes simplex using 19F nuclear magnetic resonance in a murine hepatitis model.  J. Virological      Methods, 1987, Volume 18, pp. 257-270.
41. *Kramer, B.S., Ramphal, R. and Rand, K.H.:  A Randomized Comparison of Two Ceftazidime-Containing Regimens versus Cephalothin-Gentamicin-Carbenicillin in Febrile Granulocytopenic Cancer Patients.  Antimicrob. Agents Chemother.  1986,      Volume 30(1), pp. 64-68.
42. *Rand, K.H., Houck, H.J. and Dickinson, M.:  False Positive Indirect Fluorescent Antibody (IFA) Tests for Antibody to Herpes Simplex Virus -1  (HSV-1):  Comparison of Four Commercially Available Methods. Am. J. Clin. Path.  1986, Volume 86(6), pp. 765-768.
43. *Rand, K.H., Bodor, N., El Koussi, A.A., Raad, I., Miyake, A., Houck, H. and Gildersleeve, N.:  Potential treatment of Herpes Simplex Virus Encephalitis by Brain-Specific Delivery of Trifluorothymidine using a Dihydropyridine Pyridinium Salt Type Redox Delivery System.  J. Med. Virology. 1986, Volume 20, pp. 1-8.
44. *Oblon, D.J.; Elfenbein, G.J.; Rand, K.H. and Weiner, R.S.:  Recurrent Varicella-Zoster Infection After Acyclovir Therapy in Immunocompromised Patients.  Southern Med J. 1986, Volume 79, pp. 256-257.
45. *Rand, K.H.; Houck, B.S. and Swingle, H.M.:  Rotazyme Assay in Neonates without Diarrhea.  Am J Clin Path.  1985, Volume 84, pp. 748-751.
46. *Gotz, V.P.; Rand, K.H. and Kramer, B.S.:  Effect of filtering amphotericin B infusions on the incidence and severity of phlebitis and selected adverse reactions.  Drug Intelligence & Clin. Phar.  1985, Volume 19, pp. 436-439. 
47. *Rand, K.H.; Rayfield, M.A. and Berns, K.I.:  Recovery of herpes simplex type-1 from the celiac ganglion of a renal transplant patient. Southern Med J. 1984, Volume 77, pp. 403-404.
48. *Kramer, B.; Carr, D.; Rand, K.H.; Pizzo, P.; Johnson, A.; Robichaud, K. and Yucha, J.: Prophylaxis of fever and infection in adult cancer patients:  A placebo-controlled trial of oral trimethoprim- sulfamethoxizole plus erythromycin.  Cancer  1984, Volume 53, pp. 329-335.
49. *Rand, K.H.; Jacobsen, D.G.; Cottrell, C.R.; Koch, K.L.; Guild, R.T. and McGuigan, J.E.:  Antibodies to herpes simplex type I in patients with active duodenal ulcer.  Arch. Internal Med.  1983, Volume 143, pp. 1917-1920.
50. *Ramphal, R.; Kramer, B.S.; Rand, K.H.; Weiner, R.S. and Shands, J.W.:  Early results of a comparative trial of ceftazidime versus cephalothin carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients.  J. Anti Chem.  1983, Volume 12, pp. 81-88.
51. *Pollard, R.B.; Arvin, A.M.; Gamberg, P.; Rand, K.H.; Gallagher, J.G. and Merigan, T.C.:  Specific cell mediated immunity and infections with cytomegalovirus, herpes simplex virus and varicella-zoster virus in cardiac transplant recipients.  Amer. J. Med. 1982, Volume 73(5), pp. 679-687.
52. *Rand, K.H.; Kramer, B. and Johnson, T.: Cancer chemotherapy associated symptomatic stomatitis:  Role of herpes simplex virus (HSV).  Cancer  1982, Volume 50, pp. 1262-1265.
53. *Landis, S.J.; Ramphal, R.; Mansheim, B.J.; Rand, K.H. and Shands, J.W., Jr.:  Comparative efficacy of Piperacillin and Penicillin G in the treatment of Gonococcal Urethritis.  Antimicrob. Agents Chemother.  1981, Volume 20, pp. 693-695.
54. *Rand, K.H.; Rosenbloom, A.L.; Maclaren, N.K.; Silverstein, J.H.; Riley, W.J.; Butterworth, B.; Yoon, J.W.; Rubenstein, A.H. and Merigan, T.C.:  Human leukocyte interferon treatment of two children with insulin dependent diabetes.  Diabetologia  1981, Volume 21(2), pp. 116-119.
55. *Rand, K.H.:  Isolation of herpes simplex virus type-1 from gastric contents of a patient with acute pancreatitis. South Med. J.  1981, Volume 74, pp. 489-491.
56. *Merigan, T.C.; Rand, K.H.; Pollard, R.B.; Abdallah, P.S.; Jordan, G.W. and Fried, R.P.:  Administration of human leukocyte interferon in herpes zoster:  II Preliminary controlled trials to establish effective dosage in patients with malignancy.  New Engl. J.  Med.  1978, Volume 298, pp. 981-987.
57. *Rand, K.H.; Pollard, R.B. and Merigan, T.C.:  Increased pulmonary superinfections in cardiac transplant patients undergoing primary cytomegalovirus infection.  New Engl. J. Med.  1978, Volume 298, pp. 951-953.
58. *Pollard, R.B.; Rand, K.H.; Arvin, A. and Merigan, T.C.:  Cell mediated immunity to cytomegalovirus infection on normal persons and cardiac transplant recipients.  J. Infect. Dis. 1978, Volume 137, pp. 541-549.
59. *Rand, K.H.; Rasmussen, L.E.; Pollard, R.B.; Arvin, A. and Merigan, T.C.:  Cellular immunity and herpes virus infections in cardiac transplant patients. New Engl. J. Med. 1977, Volume 296, pp. 1372-1377.
60. *Rand, K.H.; Johnson, K.P.; Rubenstein, L.J.; et al.:  Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy.  Use of Urine cytology to assess response to therapy.  Annals of Neurology  1977, Volume 1, pp. 458-462.
61. *Rand, K.H.; Emmons, R.W. and Merigan, T.C.:  Adult measles:  An unforeseen consequence of immunization?  JAMA  1976, Volume 236, pp. 1028-1031.
62. *Rand, K.H.; Reed, B.; Broseus, K.; Hampar, B.; Gilden, R.V. and Long, C.: Mixed-culture cytopathogenicity between KC and XC Oncornavirus indicator lines and      "virus-free" human choriocarcinoma cells.  J. Natl. Cancer Inst.  1976, Volume 56, pp. 509-512.
63. *Rand, K.H.; Davis, J.; Gilden, R.V.; Oroszlan, S. and Long, C.W.:  Fusion inhibition: Bioassay of a type C viral protein.  Virology  1975, Volume 64, pp. 63-74.
64. *Rand, K.H.; Long, C.W.; Wei, T.T. and Gilden, R.V.:  Plaque assay for the Mason-Pfizer monkey virus.  J. Nat. CA Inst.  1974, Volume 53, pp. 449-452.
65. *Long, C.W.; Good, E.; Gilden, R.V. and Rand, K.H.:  Murine sarcoma virus induced cytopathological effect in mouse cells made resistant to 6-Azauridine.  J. Gen. Virology 1974, Volume 23, pp. 185-189.
66. *Rubio, V.; Tsai, W.P.; Rand, K.H. and Long. C.:  A comparison of DNA binding proteins from normal and virus-transformed mouse cells.  Int. J. CA  1973, Volume 12, pp. 545-550.
67. *Rand, K.H. and Long, C.W.:  Fusion of a Rous Sarcoma virus transformed human cell line, KC by RD 114 virus.  J. Gen. Virology  1973, Volume 21, pp. 523-532.
68. *Hampar, G.; Rand, K.H.; Lerner, R.; Del Villano, B.C.; McAllister, R.M.; Martos, L.M.; Dere, J.G.; Long, C.W. and Gilden, R.V.:  Formation of syncytia in human lymphoblastoid cells infected with type C viruses.  Virology  1973, Volume 55, pp. 453-463.
69. *Rand, K.H. and Long, C.A.:  Syncytial assay for the putative human C-type virus RD 114, utilizing human cells transformed by Rous sarcoma virus.  Nature , New Biol.  1972, Volume 240, pp. 187-190.
70. *Yalom, I.; Houts, P.; Newell, G. and Rand, K.H.:  Preparation of patients for group therapy.  Arch. Gen. Psych.  1967, Volume 17, pp. 416-427.
71. *Yalom, I.; Houts, P.; Zimmerberg, S. and Rand, K.H.:  Prediction of improvement in group therapy.  Arch. Gen. Psych.  1967, Volume 17, pp. 159-168.
72. *Yalom, I. and Rand, K.H.: Compatibility and cohesiveness in therapy groups.  Archives of Gen. Psych.  1966, Volume 15, pp. 267-275.

         Return to:  Top of page | Dr. Rand's home page